Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 30S ribosomal subunit in Leishmania parasites is the smaller component of the mitochondrial ribosome (mitoribosome), which is distinct from the cytosolic 40S subunit. In kinetoplastid parasites like Leishmania, the mitoribosome is uniquely structured, consisting of a 30S small subunit and a 40S large subunit, which together form a 50S complex responsible for translating essential mitochondrial-encoded proteins. This subunit is a critical therapeutic target because it contains highly conserved regions, such as the aminoacyl-tRNA binding site (A-site), which are susceptible to aminoglycoside antibiotics. Drugs like paromomycin bind to this subunit, disrupting the fidelity of translation and leading to parasite cell death. Because of the structural differences between the Leishmania mitoribosome and the human mitoribosome, it offers a window for selective toxicity, although high doses can still lead to adverse effects in the host.
Inhibition of protein synthesis by binding to the decoding site (A-site) of the small ribosomal subunit, inducing mRNA misreading and premature termination of translation.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Leishmania mitochondrial 30S ribosomal subunit (30S mitoribosomal subunit).